We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA recently issued a warning letter to Charlotte, N.C.-based Alveolus stating that the company violated current good manufacturing practice (cGMP) requirements by removing its Tracheal Bronchial Stent Technology (TB-STS) from the market without proper notification.